INO - Inovio Pharmaceuticals Inc
IEX Last Trade
7.21
-0.110 -1.526%
Share volume: 207,284
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$7.32
-0.11
-1.50%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-08 | 2023-03-01 | 2023-05-10 | 2023-08-09 | 2023-11-09 | 2024-03-06 | 2024-05-13 | |
| Assets | |||||||||
| Total Assets | 459.399 M | 391.968 M | 348.533 M | 266.583 M | 233.038 M | 193.097 M | 170.951 M | 129.114 M | |
| Current Assets | 416.185 M | 350.208 M | 315.243 M | 233.896 M | 203.284 M | 174.767 M | 153.113 M | 111.683 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 56.689 M | 58.244 M | 50.506 M | 5.110 M | 3.243 M | 5.150 M | 5.414 M | 3.517 M | |
| Short Term Investments | 56.689 M | 58.244 M | 50.506 M | 5.110 M | 3.243 M | 5.150 M | 5.414 M | 3.517 M | |
| Total Receivables | 11.372 M | 10.081 M | 11.738 M | 5.035 M | 5.116 M | 2.144 M | 2.405 M | 2.551 M | |
| Current Cash | 348.125 M | 281.883 M | 252.999 M | 223.751 M | 194.925 M | 167.473 M | 145.294 M | 105.615 M | |
| Total Non-current Assets | 43.214 M | 41.760 M | 33.291 M | 32.686 M | 29.753 M | 18.330 M | 17.838 M | 17.431 M | |
| Property Plant Equipment | 16.213 M | 15.588 M | 7.728 M | 6.983 M | 6.304 M | 5.633 M | 4.961 M | 5.015 M | |
| Other Assets | 770.144 K | 701.986 K | 684.044 K | 652.517 K | 666.890 K | 605.315 K | 605.315 K | 605.315 K | |
| Intangible Assets | 2.369 M | 2.249 M | 2.130 M | 2.048 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 10.513 M | 10.513 M | 10.513 M | 10.513 M | 10.513 M | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 459.399 M | 391.968 M | 348.533 M | 266.583 M | 233.038 M | 193.097 M | 170.951 M | 129.114 M | |
| Total liabilities | 161.728 M | 125.271 M | 126.171 M | 67.369 M | 63.666 M | 54.937 M | 53.602 M | 34.672 M | |
| Total current liabilities | 131.064 M | 94.915 M | 96.868 M | 55.151 M | 51.932 M | 43.711 M | 42.570 M | 23.401 M | |
| Accounts Payable | 38.236 M | 12.633 M | 19.862 M | 11.194 M | 8.670 M | 3.192 M | 0.000 | 6.772 M | |
| Other liabilities | 56.935 K | 710.348 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 16.395 M | 16.708 M | 16.488 M | 16.771 M | 0.000 | |
| Long term debt | 16.521 M | 16.301 M | 16.615 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 56.935 K | 710.348 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 297.671 M | 266.697 M | 222.363 M | 199.214 M | 169.372 M | 138.160 M | 117.349 M | 94.442 M | |
| Common stock | 235.278 M | 249.351 M | 250.919 M | 258.438 M | 264.354 M | 268.623 M | 22.743 M | 23.292 M | |
| Retained earnings | -1.396 B | -1.433 B | -1.488 B | -1.528 B | -1.564 B | -1.598 B | -1.623 B | -1.653 B |